“Jace” was the first approved regenerative medicine product in Japan since October 2007, for the treatment of severe burns. Sales until March 2014 were 800 million Yen. Clinical trials for its application in congenital giant pitmented nevus disease have now been completed and an application for commercialization has been filed.
J-TEC news release, September 8, 2015
J-TEC completes clinical studies on autologous cultured epidermal “Jace” for treatment of congenital giant pigmented nevus bruise disease.